Sagittarius Life Science - Asset Resilience Ratio
Sagittarius Life Science (3205) has an Asset Resilience Ratio of 60.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 3205 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Sagittarius Life Science's Asset Resilience Ratio has changed over time. See 3205 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sagittarius Life Science's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Sagittarius Life Science.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$652.00 Million | 60.84% |
| Total Liquid Assets | NT$652.00 Million | 60.84% |
Asset Resilience Insights
- Very High Liquidity: Sagittarius Life Science maintains exceptional liquid asset reserves at 60.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sagittarius Life Science Industry Peers by Asset Resilience Ratio
Compare Sagittarius Life Science's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Sagittarius Life Science (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Sagittarius Life Science.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.84% | NT$652.00 Million ≈ $20.54 Million |
NT$1.07 Billion ≈ $33.76 Million |
+46.00pp |
| 2024-12-31 | 14.83% | NT$77.11 Million ≈ $2.43 Million |
NT$519.83 Million ≈ $16.38 Million |
+2.57pp |
| 2023-12-31 | 12.26% | NT$81.49 Million ≈ $2.57 Million |
NT$664.72 Million ≈ $20.94 Million |
-1.60pp |
| 2022-12-31 | 13.86% | NT$80.24 Million ≈ $2.53 Million |
NT$579.12 Million ≈ $18.25 Million |
-1.42pp |
| 2021-12-31 | 15.28% | NT$103.25 Million ≈ $3.25 Million |
NT$675.75 Million ≈ $21.29 Million |
+14.45pp |
| 2020-12-31 | 0.83% | NT$6.15 Million ≈ $193.76K |
NT$740.74 Million ≈ $23.34 Million |
+0.34pp |
| 2019-12-31 | 0.49% | NT$4.00 Million ≈ $126.02K |
NT$811.59 Million ≈ $25.57 Million |
-8.32pp |
| 2016-12-31 | 8.81% | NT$124.50 Million ≈ $3.92 Million |
NT$1.41 Billion ≈ $44.50 Million |
-- |
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.